Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. The company is on track with NDA submission and has positive clinical trial results, but faces financial challenges with a significant cash burn and net loss. The Q&A section reveals cautious optimism about pricing strategy and partnerships, but lacks clarity in some areas. The focus on cash management and the absence of priority review expectations temper the outlook. Overall, the sentiment is neutral, reflecting both potential positives and ongoing uncertainties.
Key Financial Performance
Cash, Cash Equivalents, and Marketable Securities $55.4 million as of June 30, 2025, supporting operations into the second half of 2026.
Total Operating Expenses (3 months ended June 30, 2025) $12.6 million, consistent with expectations due to increased investment in regulatory, quality, and pre-commercial planning.
Total Operating Expenses (6 months ended June 30, 2025) $25.5 million, consistent with expectations due to increased investment in regulatory, quality, and pre-commercial planning.
Net Loss (3 months ended June 30, 2025) $12.7 million, reflecting increased investment in regulatory and pre-commercial activities.
Net Loss (6 months ended June 30, 2025) $25.5 million, reflecting increased investment in regulatory and pre-commercial activities.
Capital Raise $49.3 million raised through a $45 million underwritten public offering in June and an additional $4.3 million from the underwriters' overallotment option.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Drug Application (NDA) Submission: Achieve Life Sciences submitted an NDA for cytisinicline as a treatment for nicotine dependence for smoking cessation to the FDA. The submission includes data from over 2,000 clinical trial participants and long-term safety data from the ORCA-OL study.
Clinical Trial Results: The NDA submission is supported by results from two Phase III studies (ORCA-2 and ORCA-3) and long-term safety data from over 300 participants who completed at least 6 months of treatment.
Patient Feedback: 98% of survey respondents believe cytisinicline helped them reduce or stop nicotine dependence, and 99% would recommend it to others.
Market Opportunity: 29 million Americans smoke, with over 15 million attempting to quit annually. The market for smoking cessation is significant, with public health costs exceeding $600 billion annually in the U.S.
Strategic Partnership: Achieve partnered with Omnicom to leverage their expertise in healthcare marketing and product launches, preparing for a potential 2026 launch of cytisinicline.
Capital Raise: Achieve raised $49 million, including a $45 million public offering and an additional $4.3 million from underwriters, to support operations into the second half of 2026.
Regulatory Milestones: Achieve expects the FDA's 74-day NDA acceptance letter in mid-September and plans to submit a 120-day safety update in October.
Commercial Launch Preparations: Achieve is building a proprietary AI-enabled commercial platform for precision targeting and engagement, supported by Omnicom's expertise.
Reframing Nicotine Dependence: The company aims to redefine nicotine dependence as a medical condition requiring effective treatment, similar to how obesity treatments have been repositioned.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Risks: The company is awaiting FDA approval for its new drug application (NDA) for cytisinicline. Any delays or rejection in the regulatory process could significantly impact the company's timeline and financial projections.
Safety Data Requirements: The FDA has requested long-term safety data, including over 100 participants completing one year of treatment. Failure to meet these requirements or any adverse findings could delay approval or impact market acceptance.
Commercial Launch Risks: Launching a drug as a small company is inherently high-risk. The company acknowledges the challenges of scaling operations, ensuring product availability, and achieving market penetration.
Market Access and Pricing Challenges: Securing insurance coverage and favorable pricing for cytisinicline is critical. Any missteps in pricing strategy or payer negotiations could limit patient access and reduce revenue potential.
Financial Risks: The company reported a net loss of $12.7 million for Q2 2025 and is reliant on its recent $49 million capital raise to fund operations into the second half of 2026. Any unforeseen expenses or delays could strain financial resources.
Competitive Pressures: The smoking cessation market is competitive, and the company must differentiate cytisinicline from existing therapies. Failure to effectively communicate its value proposition could hinder adoption.
Supply Chain and Distribution Risks: The company is in the process of finalizing partnerships for logistics and distribution. Any disruptions or delays in these areas could impact the product's availability at launch.
Strategic Execution Risks: The company is heavily reliant on external partners like Omnicom for its commercial strategy. Any misalignment or underperformance by these partners could jeopardize the launch.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Review and Approval Timeline: The company expects to receive the FDA's 74-day letter in September 2025, which will confirm the acceptance of the NDA submission for cytisinicline. The 120-day safety update will be submitted in October 2025, and the company anticipates a potential product approval decision in late 2026.
Commercial Launch Preparations: Achieve is preparing for a potential launch of cytisinicline in late 2026. The company has partnered with Omnicom to execute its commercial launch strategy, including brand development, market access, and patient/provider engagement. A proprietary AI-enabled commercial platform will be used to optimize targeting and engagement.
Market Access and Pricing Strategy: The company is finalizing its pricing strategy and payer segmentation plans. Pre-approval information exchange with payers is expected to begin in Q4 2025, with outsourced account managers starting field work in Q1 2026. The focus is on securing insurance coverage and favorable pricing for cytisinicline.
Regulatory and Safety Data Milestones: The ORCA-OL study has achieved critical safety data milestones, with over 290 participants completing one year of cytisinicline treatment. Final study results will be locked by the end of 2025, and the data will be used to support FDA review and future publications.
Financial Position and Funding: The company has raised $49 million in capital, providing a cash runway into the second half of 2026. This funding will support regulatory, commercial, and operational initiatives leading up to the anticipated product launch.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Cindy, just a quick one for you just to confirm, in the 120-day safety update, will you submit only 100 patients or the full 290 that you now have access to?
A:We'll be submitting all of the subjects at the time of the database cut that occurred in June. So it will be more than 100, but not exactly the 290 over the 200 that we have right now.
Q:Rick, you mentioned launch in late '26. And if we assume an approval in late June, how should we think about your ramp in commercial spending ahead of launch? Is it going to be completely approval dependent? Or will you begin ramping that spend, let's say, first half of next year?
A:It will be incremental. We have to invest in the pre-commercial activities prior to the approval. You'll see an increase over the coming quarters, but as soon as we reach approval, then you'll see an increase. We keep a very disciplined approach to that commercial investment. Once we've got the NDA acceptance, you'll start to see a ramp-up, but not excessive.
Q:Jaime, are you assuming that a premium price relative to the generic CHANTIX will be available to you? Or should we be thinking about something closer to the generic pricing that we see today?
A:We would view this as a branded product at a premium price. That resonates based on the profile and what we are able to differentiate versus the current options. Payers aren't in disagreement with that.
Q:Jaime, on the initial contact method for reaching out to providers, can you walk us through all those initial contact methods and the flow chart based on the response?
A:That's still yet to be determined. We want to identify the individual needs of the physicians we are targeting and meet them where they are. Engagement opportunities include social, e-mail, in-person reps, and virtual reps. It will depend on what we define further through our targeting exercise.
Q:Gary, back to the full safety data for the 290 patients at 12 months. Any commentary on the overall safety profile, if it was consistent with the 6-month data? And how will you be releasing that, assuming after you provide the updated safety data to FDA at 120 days?
A:For the 120 safety day update, we will be submitting it in October. The data has been reviewed by the Data Safety Monitoring Committee, and there have been no different or unique safety signals. It is consistent with what we would expect at 6 months and 1 year.
Q:Are there any communications with the FDA prior to the day 74 letter? Or is that the first time that you hear back from them?
A:Normally, at this time, there's back and forth with FDA, and that's what we're experiencing. They are contacting us, asking where various things are, and we are responsive. It is a normal back-and-forth process.
Q:Any chance for a priority review, or are you anticipating a standard review?
A:At this point, we are anticipating a standard review. However, we are hopeful for a priority review and have requested it. We have also requested the new Commissioners National Priority Voucher, but we don't view it as a likely possibility.
Q:Jaime, regarding the Omnicom partnership, any specific work that you're doing together right now in the early days while you wait for the approval or better visibility on timelines? Does it make sense to do any unbranded marketing to physicians to get them comfortable?
A:We have engaged all 7 of our agencies and are fully operational with high-priority activities to inform launch and resource deployment. We are building our launch road map and AI-enabled platform for seamless functional area integration. Early focus is on driving the message that a new treatment is coming and elevating the seriousness of conversations. Product-specific work will come closer to launch.
Q:Rick, any update on the synthetic version of cytisinicline, timing of that potentially? And are there any partnership discussions that have progressed, specifically with some comorbid conditions like COPD?
A:We are continuing to work on the potential for the synthetic version, but our focus has been on the NDA submission. Partnership discussions will progress further now that the NDA has been submitted.
Q:Justin, do you expect your partnership with Omnicom to impact potential discussions with more traditional pharma partners?
A:It's all complementary. The Omnicom platform is fully functional, and additional resources will be brought in as required. Omnicom's credibility adds value to our launch package and market drive.
Q:Boris, can we expect any updates on future clinical development road map before the end of the year? And do you plan to share any interim results from the ORCA-OL trial ahead of full publication?
A:We are planning on completing the entire database for the ORCA-OL study by the end of this year. We will look at conferences and publications early next year to present the data. The ongoing trial focus will allow us to proceed quickly with results in 2026.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer to the question about the initial contact methods for reaching out to providers. Jaime stated that it is still yet to be determined and will depend on further targeting exercises, which lacked specific details or clarity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA review
LLC Research
OL study
Omnicom
Research Division
activity
application
approach
approval cytisinicline
brand
capability
capital raise
comment
commitment
coverage
cytisinicline life
decision
dedication
distribution
engagement
experience
front
gratitude
health care
indication
investment
investor
market approval
message
offering
outcome
path
patient provider
precision
relationship
stakeholder
state
support belief
survey response
target
technology
value cytisinicline
work
ACHV Transcript
Achieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary and Q&A indicate a positive sentiment. The company's strategic plan shows strong product development with NDA approval and commercial launch goals. The Q&A reveals confidence in manufacturing and IP, though some details remain vague. The partnership with Adare Pharma Solutions and the AI-driven commercial platform are promising. Despite some uncertainties, the overall outlook is optimistic, with a potential market opportunity and supportive clinical data. The sentiment is positive, with a likely stock price increase in the short term.
Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reveals significant concerns: a net loss of $54.7 million, limited cash reserves, and ongoing economic and financial risks. The Q&A section highlights unproven commercial execution strategies and unclear timelines for manufacturing and regulatory approvals. While there is optimism for future product launches, the lack of finalized pricing strategies and potential supply chain issues further contribute to a negative outlook. These factors outweigh any positive aspects, suggesting a likely stock price decline in the short term.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed picture. While there are positive aspects such as the preparation for commercial launch and favorable safety outcomes, there are significant risks including regulatory approval, financial constraints, and competitive pressures. The Q&A section highlights uncertainties, particularly regarding the vaping study and funding, which could weigh on investor sentiment. Given the absence of immediate catalysts and the potential for delays, the overall stock reaction is likely to remain neutral.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call summary presents a mixed outlook. The company is on track with NDA submission and has positive clinical trial results, but faces financial challenges with a significant cash burn and net loss. The Q&A section reveals cautious optimism about pricing strategy and partnerships, but lacks clarity in some areas. The focus on cash management and the absence of priority review expectations temper the outlook. Overall, the sentiment is neutral, reflecting both potential positives and ongoing uncertainties.
ACHV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
